News

A JAMA Ophthalmology Clinical Trial of the Year enrolled 1421 eyes across 28 sites, with NEI-funded follow-up extending the findings to 5 years.

Handheld IC1000 pairs rebound tonometry with camera-guided alignment

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

Andrew G. Lee, MD, and Drew Carey, MD, break down a debate over PDE-5 inhibitor use after non-arteritic anterior ischemic optic neuropathy.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

A VR lens simulator used at InVision Eye Care lifted premium IOL conversion rates from 30%-35% to the mid-40s

Study authors discuss fishing-related eye injury patterns, pediatric risk, and prevention strategies drawn from other sports.

Women are more often affected than men, and the disease manifests differently between the sexes.

Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.

Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology.

A same-platform, prospective comparison of 123 eyes suggests diffractive trifocal optics don't compromise standard automated perimetry outside the central 5°

Survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.

Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

Esen Akpek, MD, weighs in on lifitegrast-perfluorohexyloctane phase 2 data and what it means for the drop's path to phase 3.

Antibiotic injection reduced endophthalmitis risk vs topical drops after cataract surgery, meta-analysis found.

This article discusses the evolution of the body of information about Demodex blepharitis over the years, from the convening of a consensus panel to the realization that a new drug provides rapid relief to the ocular surface.

Two optical treatment modalities can slow pediatric myopia progression without the need for pharmacologic intervention, ie, spectacle lenses incorporating highly aspherical lenslets (HAL) and orthokeratology (ortho-k) contact lenses. Both treatments are based on the same underlying theory that peripheral retinal defocus is a growth signal for axial elongation‚ but the treatments focus on different structures of the visual system, one through a manufactured spectacle lens surface (HAL) and the other through temporary corneal reshaping (ortho-k).

The agency assigned a PDUFA target action date of April 30, 2027.

Douglas D. Koch, MD, and Julie Schallhorn, MD, MS, discuss the optical designs behind EDOF lenses, where they fit in clinical practice, and advances shaping the category.

A retrospective study of nearly 1,000 patients found epithelial resolution with serial decellularized basement membrane graft use in subclinical to Stage 1 disease.

Amy Zhang, MD, discusses coverage barriers to home IOP monitoring, a surgical ergonomics habit for early-career surgeons, and glaucoma's role in burnout.

Bausch + Lomb advances dual-action dry eye drop to phase 3 and reports positive phase 1b data for TRPV1 antagonist BL1332

Angela Y. Zhu, MD, of Bascom Palmer Eye Institute, explains how to distinguish eye allergy from vision-threatening VKC and AKC in children and when steroid-sparing therapy and referral are warranted.

The over-the-counter lens is the first FDA-recognized device in its class, targeting light sensitivity in patients with episodic migraine aged 12 and older.

Large cohort links long-term tadalafil for urinary symptoms to modestly higher open-angle glaucoma risk.

A new study reported that the so-called “high-pillow sleeping position” can result in elevated intraocular pressure (IOP) values and decreased ocular perfusion pressure (OPP) in patients with glaucoma compared with sleeping in the supine position.